1.Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer.
Young Joo MIN ; Sung Jo BANG ; Jung Woo SHIN ; Do Ha KIM ; Jae Hoo PARK ; Gyu Yeol KIM ; Byung Kyun KO ; Dae Hwa CHOI ; Hong Rae CHO
Journal of Korean Medical Science 2004;19(3):369-373
Heptaplatin is a recently developed platinum derivative. This agent has been reported to have a response rate of 17% as a single agent, and tolerable toxicity in the treatment of advanced gastric cancer. The aim of this study was to evaluate the efficacy and toxicity of a combination of 5-fluorouracil (5-FU) and heptaplatin in patients with advanced gastric cancer. Forty-seven chemotherapy-naive patients with advanced or recurred gastric cancer were recruited. 5-FU was administered over 120 hr by continuous intravenous infusion from day 1 to 5, at a daily dose of 1,000 mg/m2 and heptaplatin was administered over 1 hr by intravenous infusion on day 1 at 400 mg/m2, and this cycle was repeated every 4 weeks. The response rate was 21%, median progression-free survival was 1.9 months (95% CI, 1.6 to 2.2 months). Median overall survival was 6.2 months (95% CI, 4 to 8.4 months) and the 1-yr survival rate was 29% for all patients. The most frequent toxicity was proteinuria. Toxicities were generally mild and reversible. This study demonstrates that the combination of 5-FU/heptaplatin combination is less active but tolerated in patients with advance gastric cancer.
Adult
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Disease-Free Survival
;
Female
;
Fluorouracil/*administration & dosage
;
Follow-Up Studies
;
Human
;
Male
;
Malonates/*administration & dosage
;
Middle Aged
;
Organoplatinum Compounds/*administration & dosage
;
Stomach Neoplasms/*drug therapy
;
Time Factors
;
Treatment Outcome